Eric Singhi, MD

Cecilia Brown

DocwireNews

Eric Singhi, MD, a thoracic medical oncologist at the University of Texas MD Anderson Cancer Center, shares key highlights in lung cancer from the 2024 American Society of Clinical Oncology Annual Meeting, including the trending hashtag, #ASCOLung.
“We are rebranding this as #ASCOLung because it’s such an exciting time to be a thoracic oncologist and hear about all these advances for our patients with lung cancer,” Dr. Singhi said.
He spoke about how it felt to witness multiple presentations on historic advancements in lung cancer during the annual meeting.
“This is an unprecedented moment,” Dr. Singhi said. “It’s the first time where we had 3 lung cancer trials that were featured at the crown jewel session, the plenary session…and it was a monumental, unprecedented experience. A lot of us thoracic medical oncologists were in the front row seats just to get the data in real time and appreciate it and better understand it.”
Dr. Singhi broke down the key highlights from the plenary session, including a <a href="https://www.docwirenews.com/post/david-spigel-md-on-how-the-phase-3-adriatic-trial-changes-the-standard-of-care-for-ls-sclc">major update in small cell lung cancer</a> (SCLC) from David R. Spigel, MD.
“One of the studies that we were really excited about was the ADRIATIC study, and that’s looking at how we can potentially practice-change the treatment that we’re giving our patients with limited-stage [SCLC],” Dr. Singhi said. “For decades, we’ve been using concurrent or definitive chemoradiation therapy for these patients and trying to do better… what we saw yesterday is something that I believe is practice changing. We’re going to be able to bring immune checkpoint blockade into the earlier setting for our patients.”
Dr. Singhi also highlighted data from the <a href="https://www.docwirenews.com/post/a-new-standard-of-care-dr-ramalingam-discusses-laura-results-implications-with-the-two-onc-docs" target="_blank" rel="noopener">phase 3 LAURA trial</a>, a double-blinded and placebo-controlled phase 3 trial, that assessed the efficacy and safety of osimertinib in adults with unresectable stage III EGFR-mutated non-small cell lung cancer who received definitive platinum-based concurrent or sequential chemoradiotherapy and did not have progression.
“We’ve seen this theme throughout the years, now [we’re] looking to see for stage III unresectable disease after chemoradiation therapy: Does osimertinib versus placebo really lead to an improvement? We saw that there was definitely a significant progression-free survival benefit,” Dr. Singhi said.

Katy Marshall

Evaluating the Potential Benefits of Extended Post-Operative Follow-up in Gastric Cancer

Gastric Cancer

DocWire News Editors

What is Demodex Blepharitis?

Demodex Blepharitis

Katie Kosko

How PATP May Benefit Patients With Lung Cancer Who Are at Risk of VTE

Lung Cancer

Latest News

Dr. Eric Singhi on an ‘Unprecedented Moment’ in Lung Cancer

ASCO 2024: Focus on Lung Cancer

Eric Singhi, MD, a thoracic medical oncologist at the University of Texas MD Anderson Cancer Center, shares key highlights in lung cancer from ASCO 2024.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Onc Brothers Event

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Diabetes

Oncology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe